Vaxdigm's partnership

PARTNERSHIP

NDA/ Joint R&D agreement signedImplementation of RNA-interaction-domain-based protein solubility improvement, development of protein manufacturing technology including a pentameric recombinant protein vaccine platform

NDA signed Effectiveness analysis of vaccine candidates and developed a biomolecular imaging technique related to the action mechanism

NDA signedE.Coli vaccine manufacturing process standardization protocol development

MOU signedPre-clinical and clinical development and progression regarding vaccine candidate materials both domestically and internationally

NDA signedJoint innovation of nano-pharmaceuticals using proprietary technology from both Vaxdigm and Therabest

Licensing-out joint R&D agreement signedPre-clinical and clinical development and progression regarding vaccine candidate materials both domestically and internationally

MOU signedVaccine technology and platform development cooperation/ production and verification of (pre)clinical GLP test drugs for vaccine development

Joint development Developed and out-licensed technology for cost-effective vaccines targeting LMICs

NDA signedDeveloped a cost-effective process for Ildong protein pharmaceuticals using Vaxdigm’s propiertary technology